Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Vericel Corporation

Vericel Corporation (VCEL) Stock Overview

Explore Vericel Corporation’s financial performance, market position, analyst ratings, and future outlook.

VCEL●NASDAQ
HealthcareBiotechnology
$43.22
$0.92(2.17%)
U.S. Market opens in 12h 20m

Vericel Corporation (VCEL)

Meyka AI Score

Z

Key Financials

Market Cap2.2B
P/E Ratio89.73
EPS (TTM)$0.47
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$40.15
3 Months$53.09
1 Year Target$43.61

VCEL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Vericel Corporation (NASDAQ: VCEL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Vericel Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VCEL on the NASDAQ shows an RSI of 43.69, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $43.61 for the NASDAQ listing.

Key metrics behind Vericel Corporation's NASDAQ-traded stock include a P/E ratio of 89.73 and a market capitalization of 2.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VCEL on the NASDAQ.

Price Performance (NASDAQ: VCEL)

1-Day Change
2.17%
5-Day Change
0.91%
1-Month Change
-4.06%
3-Month Change
23.59%
6-Month Change
16.53%
Year-to-Date (YTD) Change
20.02%
1-Year Change
20.76%
3-Year Change
33.07%
5-Year Change
-19.62%
All-Time (Max) Change
-96.14%

Contact Information

https://vcel.com
617 588 5555
25 Blue Sky Drive, Burlington, MA, 01803

Company Facts

3,980 Employees
IPO DateFeb 4, 1997
CountryUS
Actively Trading

Frequently Asked Questions